We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
-$367M
Cap. Flow
-$23.4M
Cap. Flow %
-1.48%
Top 10 Hldgs %
42.1%
Holding
79
New
5
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$7.59M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.6M
4
ETNB
89bio
ETNB
+$4.23M
5
COGT icon
Cogent Biosciences
COGT
+$2.9M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$24.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.5M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$5.55M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
51
Black Diamond Therapeutics
BDTX
$96.8M
$4.96M 0.31%
2,014,858
– –
BLSA
52
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.95M 0.31%
500,000
– –
THRX
53
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$4.93M 0.31%
892,057
– –
PANA
54
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.31%
500,000
– –
ORIC icon
55
Oric Pharmaceuticals
ORIC
$1.15B
$4.72M 0.3%
1,054,000
– –
EQRX
56
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.69M 0.3%
1,000,000
– –
ETNB
57
DELISTED
89bio
ETNB
$4.51M 0.29%
+1,400,000
New +$4.23M
RNAC icon
58
Cartesian Therapeutics
RNAC
$229M
$4.3M 0.27%
109,469
– –
OBIO icon
59
Orchestra BioMed
OBIO
$238M
$3.98M 0.25%
400,000
– –
BCEL
60
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.94M 0.25%
2,202,333
– –
COGT icon
61
Cogent Biosciences
COGT
$6.65B
$3.83M 0.24%
+425,000
New +$2.9M
SLDB icon
62
Solid Biosciences
SLDB
$794M
$3.29M 0.21%
355,735
– –
MREO
63
Mereo BioPharma
MREO
$54.7M
$2.52M 0.16%
+2,250,000
New +$1.74M
CDAK
64
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$2.45M 0.16%
850,065
– –
EPIX
65
DELISTED
ESSA Pharma
EPIX
$2.28M 0.14%
724,500
– –
IRON icon
66
Disc Medicine
IRON
$2.94B
$2.2M 0.14%
43,333
– –
OMEG
67
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.97M 0.12%
200,000
– –
BCAB icon
68
BioAtla
BCAB
$5.46M
$1.96M 0.12%
13,727
– –
ALGS icon
69
Aligos Therapeutics
ALGS
$26.2M
$1.85M 0.12%
61,042
– –
LITS
70
Lite Strategy Inc
LITS
$32.8M
$1.76M 0.11%
145,655
– –
ELEV
71
DELISTED
Elevation Oncology
ELEV
$1.22M 0.08%
872,780
– –
TARA icon
72
Protara Therapeutics
TARA
$220M
$613K 0.04%
209,227
– –
CABA icon
73
Cabaletta Bio
CABA
$437M
$572K 0.04%
540,000
– –
NUVB.WS
74
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$75K ﹤0.01%
266,666
– –
BLCM
75
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$68K ﹤0.01%
56,950
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Boxer Capital held 79 positions worth $1.58B, down 19% from $1.95B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Boxer Capital's Q2 2022 filing shows 5 new, 1 increased, 2 reduced and 3 closed positions. Its largest new stake was Sarepta Therapeutics: 200,000 shares worth $15M. The largest sale was iTeos Therapeutics, an estimated $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2022 buy was Sarepta Therapeutics: 200,000 shares worth $15M.
  • Boxer Capital added most to Turning Point Therapeutics, Inc. Common Stock in Q2 2022, an estimated $7.59M increase.
  • Boxer Capital's biggest Q2 2022 reduction was iTeos Therapeutics, cutting an estimated $24.6M.
  • Boxer Capital fully exited Ultragenyx Pharmaceutical in Q2 2022, selling an estimated $14.5M.
  • Boxer Capital's ten largest holdings make up 42% of its $1.58B portfolio in Q2 2022.
  • Boxer Capital opened 5 new positions and closed 3 in Q2 2022.
  • Boxer Capital's portfolio value fell 19% quarter-over-quarter to $1.58B.

Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.